tradingkey.logo

Bionano Genomics Inc <BNGO.OQ> expected to post a loss of $2.41 a share - Earnings Preview

ReutersAug 12, 2025 8:14 PM
  • Bionano Genomics Inc BNGO.OQ BNGO.O is expected to show a fall in quarterly revenue when it reports results on August 14 for the period ending June 30 2025

  • The San Diego California-based company is expected to report a 12.1% decrease in revenue to $6.832 million from $7.77 million a year ago, according to the mean estimate from 4 analysts, based on LSEG data.The company's guidance on May 14 2025, for the period ended June 30, was for revenue between $6.30 million and $6.80 million.

  • ​LSEG's mean analyst estimate for Bionano Genomics Inc is for a loss of $2.41 per share.

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."

  • The mean earnings estimate of analysts was unchanged in the last three months. ​

  • Wall Street's median 12-month price target for Bionano Genomics Inc is $8.00, about 63.4% above its last closing price of $2.93

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Mar. 31 2025

-3.32

-3.02

-1.15

Beat

61.9

Dec. 31 2025

-6.00

-15.83

Missed

-163.8

Sep. 30 2024

-11.92

-12.60

-24.00

Missed

-90.5​

Jun. 30 2024

-24.74

-25.00

-13.20

Beat

47.2

​​Mar. 31 2024

-38.68

-38.70

-30.60

Beat

20.9

Dec. 31 2023

-52.16

-52.35

-24.60

Beat

53​

Sep. 30 2023

-55.33

-58.20

-60.00

Missed

-3.1

Jun. 30 2023

-60.00

-62.00

-74.40

Missed

-20

This summary was machine generated August 12 at 20:14 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI